Yes. And the company's thesis is that our drugs, which are S1 agonist like PRE-084, are safer, and that they're worth testing in humans with real disease to see if the MOA is truly therapeutic.
And so the dissembling of formerly valid proclamations on hidden S1 antagonists by a competent researcher. I suspect the importance of clinical trials vs "mouse(murine)" models are a little clearer now.